Publicacións nas que colabora con Isabel Martín Herranz (14)

2024

  1. Observational Study to Compare Biological Drug Concentration Quantification Techniques and Immunogenicity in Patients with Immune-Mediated Diseases

    Biomedicines, Vol. 12, Núm. 4

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago

    Dermatology and Therapy, Vol. 12, Núm. 3, pp. 761-770

  2. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

  3. Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis

    Frontiers in Medicine, Vol. 9

2021

  1. Continuous infusion of antibiotics using elastomeric pumps in the hospital at home setting

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 3, pp. 200-206

2020

  1. Impact of introducing assisted electronic prescription on paediatric patient safety

    Anales de Pediatria, Vol. 93, Núm. 2, pp. 103-110

2019

  1. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

  2. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  3. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. A complexity scale for clinical trials from the perspective of a pharmacy service

    European Journal of Hospital Pharmacy , Vol. 25, Núm. 5, pp. 251-256

  2. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

2017

  1. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

2016

  1. Study on adherence to treatment with imatinib in chronic: Myeloid leukaemia and its association with therapeutic response

    Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 141-149